Bevacizumab for the management of diabetic macular edema

Figure 5 Diffuse diabetic macular edema treated with bevacizumab. In the left figure, the clinical fundus photograph shows the macular edema and hard exudates at the foveal center.In the right figure, a series of optical coherence tomographys (OCTs) taken at a 24-mo follow-up can be observed. The OCT image at baseline shows the intraretinal fluid with increased central macular thickness (CMT) and best-corrected visual acuity (BCVA) = 20/100. One month after the first injection, improvement in both BCVA and CMT was observed. This result was maintained throughout the 24-mo follow-up period after six injections and with final central macular thickness within normal limits without intraretinal fluid and the improvement of BCVA to 20/30. No laser photocoagulation was performed in this case.